Sign up online today & collaborate
or click here to find out more
First data from a mid-stage trial assessing Amgen’s fully human monoclonal antibody AMG 334 show the drug to be effective in preventing migraine, one of the world’s top 10 most debilitating conditions affecting more than 10% of the population.
The global, double-blind, Phase II study met its primary endpoint by showing that AMG 334 significantly reduced monthly mean migraine days compared with placebo.For more click here
Source: Pharma Times